MedTrace Logo

Guided Optimisation of Long-term Disease rEduction in secoNdary Prevention of CVD

NCT06637657 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 5586

Last updated 2024-10-15

No results posted yet for this study

Summary

The goal of this observational study is to evaluate the implementation of a 'first-time-right' pharmacological treatment strategy in patients hospitalized with coronary artery disease.

The main question it aims to answer is:

Does early (immediately post-event) initiation of a full set of guideline-based, individualized, preventive medication lead to reductions in cardiovascular events compared to current practice (incremental titration strategies)?

Researchers will compare the 'first-time-right' strategy group to the current practice group to see if there are improvements in major adverse cardiac and cerebrovascular events (MACE) at 36 months.

Participants will:

* Receive either the 'first-time-right' strategy or current practice for secondary prevention.
* Be monitored (data collection) through routine clinical visits at baseline, 8 weeks, 12, and additional telephone contacts at 24, and 36 months after discharge.
* Complete online questionnaires at hospitalization, 8 weeks, 12, 24, and 36 months after discharge.

Conditions

  • Acute Coronary Syndrome

Interventions

OTHER

No intervention (observational study)

No intervention, only guideline implementation (observational study)

Sponsors & Collaborators

  • Dutch Network for Cardiovascular Research (WCN), Utrecht

    collaborator UNKNOWN

  • Novartis Pharmaceuticals

    collaborator INDUSTRY

  • Amarin Pharma Inc.

    collaborator INDUSTRY

  • Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

    lead OTHER

Principal Investigators

  • Marjolein Snaterse, dr. · Amsterdam UMC

  • Fabrice M.A.C. Martens, Prof. dr. · Amsterdam UMC

  • Harald T. Jorstad, dr. · Amsterdam UMC

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-09
Primary Completion
2029-01-31
Completion
2029-01-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06637657 on ClinicalTrials.gov